Identification and Confirmation of Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement and Characterization of Treatment Patterns and Outcomes in a Real-World Setting: A US Retrospective Chart Review
Acta Haematologica · 05.07.2025 · 149 (3) · 252-262
DOI: 10.1159/000546910 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Haematologica, online erschienen am 05.07.2025. Verfasst von Shreekant Parasuraman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Incyte Corporation, Wilmington, Delaware, USA, sparasuraman@incyte.com. Hauptthemen laut MEDLINE: Receptor, Fibroblast Growth Factor, Type 1, Hematologic Neoplasms, Gene Rearrangement, Myeloproliferative Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 rearrangement (MLN-FGFR1) are rare, heterogenous, aggressive hematologic malignancies with FGFR1 rearrangements at the 8p11 locus. Pemigatinib, a potent selective inhibitor of FGFR1-3, is approved for relapsed/refractory MLN-FGFR1.
Methods
This retrospective chart review included US adults with myeloproliferative neoplasm, unclassifiable (MPN-U), myelodysplastic syndrome (MDS)/MPN, post-MPN acute myelogenous leukemia, precursor T- or B-cell acute lymphoblastic leukemia/lymphoma, or mixed-phenotype acute leukemia with bone marrow biopsy and standard cytogenetic and/or molecular results. Probable cases of MLN-FGFR1 were identified and confirmed with cytogenetic or molecular testing results. Patient characteristics, diagnostic testing methods, treatments, and outcomes were abstracted.
Results
Of 560 submitted cases, 51 (9.1%) were probable MLN-FGFR1, 33 (5.9%) of which were subsequently confirmed. Among patients with confirmed MLN-FGFR1, 8p11 translocation or FGFR1 rearrangements were detected with standard cytogenetics in 72.7%, break-apart fluorescence in situ hybridization in 66.7%, next-generation sequencing in 21.2%, and real-time polymerase chain reaction in 6.1%. All but 1 patient initiated treatment; 3 patients underwent allogenic stem-cell transplant.
Conclusion
This study highlights the importance of cytogenetic and molecular evaluations in patients with chronic/blast phase hematologic malignancies to diagnose MLN-FGFR1. This is particularly important following US approval of pemigatinib for this hematologic malignancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Incyte Corporation, Wilmington, Delaware, USA, sparasuraman@incyte.com.
- Incyte Corporation, Wilmington, Delaware, USA.
- Cardinal Health, Dublin, Ohio, USA.
Zitieren
APA
Parasuraman, S., Saverno, K., Zimmerman Savill, K. M., & Colucci, P. (2025). Identification and Confirmation of Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement and Characterization of Treatment Patterns and Outcomes in a Real-World Setting: A US Retrospective Chart Review. Acta Haematologica, 149(3), 252-262. https://doi.org/10.1159/000546910
Vancouver
Parasuraman S, Saverno K, Zimmerman Savill KM, Colucci P. Identification and Confirmation of Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement and Characterization of Treatment Patterns and Outcomes in a Real-World Setting: A US Retrospective Chart Review. Acta Haematologica. 2025;149(3):252-262. doi:10.1159/000546910
BibTeX
@article{Parasuraman2025,
author = {Parasuraman, Shreekant and Saverno, Kimberly and Zimmerman Savill, Kristin M and Colucci, Philomena},
title = {Identification and Confirmation of Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement and Characterization of Treatment Patterns and Outcomes in a Real-World Setting: A US Retrospective Chart Review},
journal = {Acta Haematologica},
year = {2025},
volume = {149},
number = {3},
pages = {252--262},
doi = {10.1159/000546910}
}
EUVIMED